Porous Microneedle Patch for Electroosmosis-Promoted Transdermal Delivery of Drugs and Vaccines

被引：19

作者：

Abe, Hiroya ^{[1
]}

Sato, Kaito ^{[1
]}

Kimura, Natsumi ^{[1
]}

Kusama, Shinya ^{[1
]}

Inoue, Daisuke ^{[1
]}

Yamasaki, Kenshi ^{[2
]}

Nishizawa, Matsuhiko ^{[1
,3
]}

机构：

[1] Tohoku Univ, Dept Finemech, Grad Sch Engn, Aoba Ku, 6-6-01 Aramaki Aza Aoba, Sendai, Miyagi 9808579, Japan

[2] Tohoku Univ, Dept Dermatol, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan

[3] Tohoku Univ, Div Estab Frontier Sci Org Adv Studies, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan

来源：

ADVANCED NANOBIOMED RESEARCH | 2022年 / 2卷 / 01期

基金：

日本科学技术振兴机构;

关键词：

electroosmosis; porous microneedles; transdermal drug deliveries; vaccines; IONTOPHORESIS; SENSORS;

D O I：

10.1002/anbr.202100066

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

A charged porous microneedle (PMN) generates the electroosmotic flow (EOF) and promotes the through-needle transport of molecules and particles, indicating its applicability for the EOF-based low-invasive transdermal delivery of drugs and vaccines. The negatively charged PMN is prepared by grafting a thin film of poly (2-acrylamido-2-methylpropanesulfonic acid) (PAMPS) onto the inner wall of the microchannels of the polyglycidyl methacrylate PMN. Promoted transport from anode to cathode is observed for albumin, Au nanoparticles (15, 50nm), and silica beads (100nm), indicating the generation of an EOF strong enough to transport these negatively charged larger size species against their electrophoretic motion. A model antigen ovalbumin (OVA) is preloaded in the PMN, and is injected to a hydrogel and a pig skin with a higher efficiency (more than 2 times) than the conventional diffusion-based passive release. These results successfully demonstrate the novel EOF-based effective injection of drugs and vaccines into the skin, achieved by the newly developed charged PMN.

引用

页数：7

共 44 条

[1] Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years Randomized, controlled, phase III trial [J].